CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population
MetadataShow full item record
Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15- represented a credible stem cell marker in GB. We first demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15- cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15- were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15- cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15- cells overtime, and both CD15+ and CD15- cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior of CD15+ cells compared with CD15- cells from the same patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15- states. Our data challenge the utility of CD15- as a cancer stem cell marker.
Glioblastoma CD15 SSEA1 Hierarchy Stem cell Cancer CANCER STEM-CELLS EMBRYONIC ANTIGEN SSEA-1 TUMOR-INITIATING CELLS ACUTE MYELOID-LEUKEMIA CLONAL EVOLUTION INTRATUMOR HETEROGENEITY NERVOUS-SYSTEM MELANOMA-CELLS MOUSE EMBRYOS IN-VITRO
Evolutionary Genomics & Modelling
License start date
Stem Cells Translational Medicine, 2015, 4 (7), pp. 822 - 831